Related Experiment Video
Updated: Dec 13, 2025
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
825
Interleukin-6 in Rheumatoid Arthritis
Franco Pandolfi1, Laura Franza2, Valentina Carusi1
1Allergy and Clinical Immunology, Fondazione Policlinico Universitario A, Gemelli IRCCS, Catholic University, 00168 Rome, Italy.
International Journal of Molecular Sciences
|July 29, 2020
Summary
Interleukin-6 (IL-6) plays a key role in rheumatoid arthritis (RA) inflammation. Anti-IL-6 therapies show promise for RA treatment, especially combined with methotrexate (MTX), though a gold standard is not yet established.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Interleukin-6 (IL-6) is a cytokine implicated in various inflammatory processes.
- IL-6 signaling is a key driver in the pathogenesis of rheumatoid arthritis (RA).
- The COVID-19 pandemic heightened interest in IL-6's role in disease.
Purpose of the Study:
- To review the immunological basis for targeting IL-6 in rheumatoid arthritis.
- To evaluate the therapeutic potential of anti-IL-6 agents in RA management.
- To discuss current and emerging treatment strategies involving IL-6 inhibition.
Main Methods:
- Literature review of immunological pathways involving IL-6 in RA.
- Analysis of clinical trial data for anti-IL-6 therapies in RA.
- Examination of combination therapies, including anti-IL-6 with methotrexate (MTX).
Main Results:
- Anti-IL-6 therapies demonstrate encouraging efficacy in RA patients.
- Combination therapy with methotrexate (MTX) appears particularly beneficial.
- Variable success rates observed, indicating a need for further optimization.
Conclusions:
- IL-6 is a viable therapeutic target in rheumatoid arthritis due to its central role in inflammation.
- Anti-IL-6 drugs represent a promising class of treatments for RA.
- Further research is needed to establish optimal anti-IL-6 treatment regimens and identify a gold standard therapy.
Related Concept Videos
01:24T Cell Types and Functions
1.9K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.9K
01:20The JAK-STAT Signaling Pathway
11.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.3K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
351
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
351